OncoMatch

OncoMatch/Clinical Trials/NCT03819101

Trial of Acetylsalicylic Acid and Atorvastatin in Patients With Castrate-resistant Prostate Cancer

Is NCT03819101 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Acetylsalicylic acid and Atorvastatin for prostate cancer.

Phase 3RecruitingGustave Roussy, Cancer Campus, Grand ParisNCT03819101Data as of May 2026

Treatment: Acetylsalicylic acid · AtorvastatinThis is a 2x2 factorial randomized, multicenter, international, open phase III trial. The primary objective is to evaluate the benefit of acetylsalicylic acid and atorvastatin on overall survival (OS) (main endpoint) for patients with castrate-resistant prostate cancer starting first line treatment for CRPC

Check if I qualify

Extracted eligibility criteria

Cancer type

Prostate Cancer

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Prior therapy

Must have received: androgen deprivation therapy (orchiectomy, LHRH agonist, LHRH antagonist) — castrate-sensitive or castration-resistant

CRPC defined as tumor progression ... while on Androgen Deprivation Therapy (orchiectomy, LHRH agonist or -antagonist)

Cannot have received: life-prolonging treatment for CRPC (abiraterone, enzalutamide, radium-223, docetaxel, cabazitaxel, sipuleucel-T)

Exception: The use of these agents together with Androgen Deprivation Therapy (ADT) for castrate-sensitive disease is allowed.

No previous use of life-prolonging treatments for CRPC (including abiraterone, enzalutamide, radium-223, docetaxel, cabazitaxel, and sipuleucel-T). The use of these agents together with Androgen Deprivation Therapy (ADT) for castrate-sensitive disease is allowed.

Lab requirements

Kidney function

calculated creatinine clearance ≥ 50 ml/min, according to the formula of cockcroft-gault

Liver function

ast and alt ≤ 3xuln and no signs for cholestasis

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify